Payment overview · 2025
General Payments
$83.67
5 reported records · 4 companies
Healthcare provider profile · identity verified
Nathaniel C Knackstedt, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HOISINGTON, KS · NPI 1023050952
Verified facts
What the public records show
CMS Open Payments records show Nathaniel C Knackstedt, DO received $83.67 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.64 | 37.8% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.56 | 23.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.31 | 19.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.16 | 19.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.67 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 549 | 100 |
| Simvastatin | Simvastatin | 512 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 83 |
| Gabapentin | Gabapentin | 497 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 78 |
| Furosemide | Furosemide | 374 | 74 |
| Lisinopril | Lisinopril | 365 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 74 |
| Losartan Potassium | Losartan Potassium | 325 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 49 |
| Metformin Hcl | Metformin Hcl | 270 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 42 |
| Eliquis | Apixaban | 210 | 34 |
| Warfarin Sodium | Warfarin Sodium | 204 | 30 |
| Montelukast Sodium | Montelukast Sodium | 193 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 192 | 24 |
| Omeprazole | Omeprazole | 179 | 33 |
| Alprazolam | Alprazolam | 164 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 32 |
| Januvia | Sitagliptin Phosphate | 141 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 132 | 17 |
| Sertraline Hcl | Sertraline Hcl | 131 | 20 |
| Allopurinol | Allopurinol | 129 | 23 |
| Jardiance | Empagliflozin | 129 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 35 |
| Tramadol Hcl | Tramadol Hcl | 108 | 28 |
| Trazodone Hcl | Trazodone Hcl | 105 | 17 |
| Carvedilol | Carvedilol | 102 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 17 |
| Famotidine | Famotidine | 86 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 80 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 17 |
| Benazepril Hcl | Benazepril Hcl | 70 | 12 |
| Meloxicam | Meloxicam | 67 | 13 |
| Lorazepam | Lorazepam | 66 | 18 |
| Celecoxib | Celecoxib | 64 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | suppressed |
| Bumetanide | Bumetanide | 62 | 14 |
| Metformin Hcl Er | Metformin Hcl | 62 | 12 |
| Novolog Flexpen | Insulin Aspart | 61 | 11 |
| Prednisone | Prednisone | 61 | 26 |
| Finasteride | Finasteride | 59 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 15 |
| Spironolactone | Spironolactone | 59 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 12 |
| Propranolol Hcl | Propranolol Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 35 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 11 |
| Glipizide | Glipizide | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | suppressed |
| Carisoprodol | Carisoprodol | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Varenicline Tartrate | Varenicline Tartrate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Fentanyl | Fentanyl | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Linzess | Linaclotide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Cartia Xt | Diltiazem Hcl | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Enskyce | Desogestrel-Ethinyl Estradiol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Me-Naphos-Mb-Hyo 1 | Methenam/Sod Phos/Mblue/Hyoscy | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.67 · 5 records | Amgen Inc. | EVENITY, LEQVIO, NURTEC ODT, STRENSIQ, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error